{
  "drug_name": "dobutamine",
  "nbk_id": "NBK470431",
  "url": "https://www.ncbi.nlm.nih.gov/books/NBK470431/",
  "scraped_at": "2026-01-11T15:28:18",
  "sections": {
    "indications": "According to the FDA, dobutamine use is contraindicated in patients with a noted history of allergic reactions to either previous dobutamine use or any sulfite use. The medication is contraindicated in patients with hypokalemia, idiopathic hypertrophic sub-aortic stenosis, acute myocardial infarction, unstable angina, left main stem disease, severe hypertension, arrhythmias, acute myocarditis or pericarditis, and hypokalemia.\n\nBox Warnings\n\nIncrease in heart rate or blood pressure:\nDobutamine hydrochloride can significantly elevate heart rate and/or blood pressure, particularly systolic pressure. Clinical studies have shown that approximately 10% of adult patients experience a heart rate increase of 30 bpm or more. In comparison, about 7.5% have a systolic pressure increase of 50 mm Hg or greater. However, these effects are reversible by reducing the dosage of the medication.\n\nAs dobutamine enhances atrioventricular conduction, individuals with atrial fibrillation are at risk of developing a rapid ventricular response. To mitigate this risk, the recommendation is to administer a digitalis preparation, such as digoxin, before initiating dobutamine therapy. Patients with preexisting hypertension also have a higher likelihood of experiencing an exaggerated pressure response. Therefore, careful blood pressure monitoring is essential to manage the condition effectively.\n\nEctopic activity:\nDobutamine can induce or exacerbate ventricular ectopic activity; incidents of dobutamine directly causing ventricular tachycardia are infrequent.\n\nHypersensitivity:\nOccasional reports have indicated hypersensitivity reactions associated with the administration of dobutamine in 5% dextrose injection, USP. These reactions may include skin rash, fever, eosinophilia, and bronchospasm. Dobutamine in 5% dextrose injection contains sodium bisulfite, a sulfite compound. Sulfites have the potential to cause allergic-type reactions, ranging from anaphylactic symptoms or severe allergic reactions to less severe episodes of asthma in susceptible individuals. The prevalence of sulfite sensitivity in the general population is uncertain but believed to be low. However, sulfite sensitivity is observed more frequently in individuals with asthma than those without asthma.\n\nWarnings and Precautions\n\nGeneral:\nWhen administering dobutamine, continuously monitoring the patient's ECG and blood pressure is essential. This monitoring allows for close observation of any changes in heart rhythm and blood pressure response. Additionally, monitoring pulmonary wedge pressure and cardiac output can provide valuable information for ensuring the safe and effective dobutamine infusion. Hypovolemia should be assessed before initiating treatment with dobutamine.\n\nAdministration following acute myocardial infarction:\nClinical knowledge regarding the use of dobutamine after myocardial infarction is limited, making it challenging to determine the drug's safety in this specific scenario. Caution is necessary because any medication that enhances contractile force and heart rate might exacerbate ischemia, potentially leading to a more significant infarction. However, it is uncertain if dobutamine has such an effect.\n\nDrug interactions:\nDobutamine is contraindicated for concomitant use with dihydroergotamine (synergistic effects) or phenelzine (additive effects). Both combinations can increase the risk of severe hypertension, including hypertensive crisis.\n\nResearch suggests that when dobutamine and nitroprusside are coadministered, it generally leads to increased cardiac output and lower pulmonary wedge pressure than when either drug is used individually. Combining dobutamine with catechol-O-methyltransferase (COMT) inhibitors such as entacapone may have potential effects such as an elevated heart rate, arrhythmias, and alterations in blood pressure.",
    "mechanism": "Dobutamine is a pharmacological agent with ionotropic and chronotropic effects depending on the dose. Inotropic effects on the myocardium occur by selectively binding and activating the β-1 receptors.\n[7]\nThe medication is indicated for decompensated congestive heart failure because of the sympathomimetic effects. Dobutamine's ionotropic effect increases contractility, leading to decreased end-systolic volume and, therefore, increased stroke volume. The increase in stroke volume augments the heart's cardiac output (see\nImage.\nPressure-Volume Loop for Dobutamine).\n[8]\n\nThe changes in cardiac output allow for the baroreceptor-mediated response to decrease systemic vascular resistance (SVR) and cause little to no change in arterial blood pressure. In addition to the well-known β-1 activity, dobutamine has some β-2 activity, which contributes to the reduction in SVR, and α-1 activity, to a lesser extent, whose vasoconstrictive effects are negated by the baroreceptor mediated response and β-2 activity.\n\nPharmacokinetics\n\nThe majority of clinical studies with dobutamine have been limited to short-term duration, typically not exceeding several hours. In the limited cases where patients were monitored for 24, 48, and 72 hours, researchers observed that some individuals exhibited a sustained elevation in cardiac output. In contrast, others experienced a return toward baseline levels. Dobutamine typically has an onset of action 1 to 2 minutes after administration. However, achieving the maximum impact of an infusion rate may take up to 10 minutes. In humans, the plasma half-life of dobutamine is approximately 2 minutes. The primary processes involved in the metabolism are catechol methylation and conjugation. The major excretion products found in human urine are the conjugates of dobutamine and 3-O-methyl dobutamine.",
    "administration": "Available Dosage Forms and Strengths\n\nThe medication is available as dobutamine hydrochloride 1 mg/mL, 2 mg/mL, and 4 mg/mL in 250 ml and 250 mg/20 mL IV solution.\nDobutamine administration is via extensive IV access and infusion pump for inotropic support in decompensated congestive heart failure, stress echocardiogram, and stress nuclear testing. Dobutamine is available in a solution as a racemic mixture of both positive and negative enantiomers for IV administration. The positive enantiomer in the solution is predominately selective for the β-sympathetic receptors, mainly β-1 and β-2. In contrast, the negative enantiomer is selective for the α-1 receptors.\n[9]\n\nAdult Dosages\n\nDobutamine dosage for cardiac decompensation in heart failure can begin with a low dose of 0.5 to 1.0 mcg/kg/min and increase to a maximum of 40 mcg/kg/min. The lower doses of dobutamine can be prescribed at 2.5 to 5.0 mcg/kg/min, and the higher end of dobutamine doses can be 5.0 to 20.0 mcg/kg/min.\n[10]\nBefore administration, parenteral drug products should be visually inspected for particulate matter and discoloration, as long as the solution and container allow for the inspection.\n\nThe infusion rate should then be adjusted at short intervals, considering the patient's response. Factors such as systemic blood pressure, frequency of ectopic activity, heart rate, urine flow, and, whenever possible, central venous pressure measurements, cardiac output, and/or pulmonary capillary wedge pressure should guide the titration process. Optimal infusion rates have varied between patients in reported trials, typically ranging from 2 to 20 mcg/kg/min, slightly below this range. In rare instances, infusion rates as high as 40 mcg/kg/min are necessary to achieve the desired effect. The stress echocardiogram and stress nuclear test dose is initiated at 5 mcg/kg/min and can be increased in intervals of 10 mcg/kg/min every 3 to 5 minutes until the target heart rate is reached.\n\nSpecific Patient Populations\n\nPregnancy considerations:\nResearch on administering the drug to pregnant patients has not been conducted, and it should be employed only when the anticipated benefits significantly outweigh the potential risks to the developing fetus.\n[11]\n\nPediatric considerations:\nDobutamine has demonstrated the ability to enhance cardiac output and systemic pressure in pediatric patients across all ages. However, dopamine is more effective in premature neonates than dobutamine in increasing systemic blood pressure without causing excessive tachycardia. Evidence does not suggest that dobutamine provides any additional advantages when administered to infants who are already receiving optimal dopamine infusions.\n\nOlder patients:\nThe clinical trials conducted on dobutamine did not involve an adequate number of participants aged 65 and older to establish whether they exhibit different responses compared to younger individuals. However, observations from other clinical reports have not indicated any notable variations in the drug's effects between older adults and younger patients. As a general guideline, cautious dosing is recommended for patients 65 and older, typically starting at lower doses within the prescribed range. This approach considers the higher likelihood of reduced hepatic, renal, or cardiac function and the presence of concurrent illnesses or drug treatments.",
    "adverse_effects": "Dobutamine administration can lead to possible adverse reactions, mainly due to sympathomimetic activity.\n[12]\nMost patients taking this medication have experienced a rise in systolic blood pressure from 10 to 20 mm Hg and an increase of 5 to 10 beats per minute (bpm) in their heart rate. Increased systolic blood pressure and heart rate have been reported. In about 10% of the patients, a rise of 30 bpm or more in the heart rate is expected, and in about 7.5% of patients, a 50 mm Hg or more increase in the systolic blood pressure is expected. Patients with preexisting hypertension are more susceptible to the adverse effects on systolic blood pressure when using dobutamine.\n[13]\n[14]\n\nDobutamine increases the risk of rapid ventricular response in patients with preexisting atrial fibrillation. The recommendation for these patients is to use a regimen of digoxin before starting dobutamine to decrease the risk of developing atrial fibrillation with a rapid ventricular response. An increased risk of developing premature ventricular beats is evident during the administration of dobutamine. About 5% of patients experience premature ventricular beats.\n[15]\n\nOther adverse effects caused by this medication include hypotension rarely. While increases in systolic blood pressure are common due to dobutamine, hypotension occurs less frequently due to decreased SVR. Recommendations include reducing the dose or discontinuing the drug to reverse the hypotensive effects.\n\nPhlebitis at the site of the IV administration can occur but is an uncommon reaction.\n[16]\nDobutamine can rarely reduce potassium concentrations to hypokalemic levels. Other rare adverse effects have occurred in 1% to 3% of the patients, including nausea, headaches, chest pain, palpitations, and shortness of breath. Dobutamine contains sulfite, which can lead to reactions in rare patients with sulfite hypersensitivity.\n[17]",
    "monitoring": "With the administration of dobutamine, continuous monitoring using a cardiac monitor and blood pressure checks are recommended because dobutamine is typically given to unstable patients and can lead to serious effects quickly that require monitoring and corrective action. The clinician can reduce the dose of dobutamine or stop the medication if the patient experiences adverse effects.",
    "toxicity": "Dobutamine toxicity is rare, and the half-life is short at 2 minutes. Symptoms are generally due to sympathetic overstimulation and can include chest pain, palpitations, headaches, tremors, shortness of breath, nausea, and vomiting. IV metoprolol can be given to reverse the tachycardia caused by dobutamine."
  }
}